Development of biomarkers for psychiatric disorders (schizophrenia, mood disorders, dementia) by cerebrospinal fluid

Development of biomarkers for psychiatric disorders (schizophrenia, mood disorders, dementia) by cerebrospinal fluid - Development of biomarkers for psychiatric disorders (schizophrenia, mood disorders, dementia) by cerebrospinal fluid

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038699

Enrollment

Registered

2021-11-27

Start date

2018-10-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia, mood disorder, dementia

Interventions

Cerebrospinal fluid examination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inpatients with schizophrenia, mood disorders and dementia

Exclusion criteria

Exclusion criteria: Exclude high-risk patients such as Bleeding tendency, heparin use, anesthesia allergies,increased brain pressure, or patients judged to be inappropriate by a doctor.

Design outcomes

Primary

Measure	Time frame
Positive and negative symptom rating scale (PANSS) for schizophrenia, Hamilton depression rating scale (GRID-HAM-D) for mood disorders, or Young Mania Rating Scale, and Mini Mental State Examination (MMSE) for dementia	—

Countries

Japan

Contacts

Public ContactHiroshi Tateishi

Saga University Hospital Department of Psychiatry

tateishh@cc.saga-u.ac.jp0952-34-2304

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026